Julio C. Chávez - Concepedia

Author

Julio C. Chávez

Also Known As

Chávez, Julio, Erika Eksioglu, J CHAVEZ, J Chavez, J. C. Chavez, J. Chavez, J.C Chavez, J.C. Chavez, JULIO CHAVEZ, Jenifer I. Acevedo Chávez

608

Publications

19.2K

Citations

H-Index

Concepts

All Affiliations

Moffitt Cancer Center The University of Texas MD Anderson Cancer Center University of South Florida Dana-Farber Cancer Institute Banner MD Anderson Cancer Center

About

Julio C. Chávez is an author at Moffitt Cancer Center specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	5.3K
2	Health Sciences	13	13	538
3	Blood Transplantation	4	4	148
4	Cell Biology	2	2	110
5	Engineering	1	1	29

Julio C. Chávez

127

Publications

17.2K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaAxicabtagene CiloleucelMedicineImmunology	2018	2.2K
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Journal of Clinical Oncology	2020	752
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Molecular Therapy	2017	601
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, The Lancet Oncology Lymphoid NeoplasiaAxicabtagene CiloleucelMedicinePathologyPharmacotherapy	2021	574
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial Nathan Fowler, Michael Dickinson, Martin Dreyling, Nature Medicine Lymphoid NeoplasiaHematologyImmunologyPathologyElara Trial	2021	492
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis Adam M. Petrich, Mitul Gandhi, Borko Jovanovic, Blood	2014	461
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) Raza M. Alvi, Matthew J. Frigault, Michael G. Fradley, Journal of the American College of Cardiology	2019	328
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma Michael D. Jain, Hua Zhao, Xuefeng Wang, Blood	2021	273
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Nature Medicine	2022	266

Page 1